TolerogenixX Completes Last Patient Transplant in Phase IIb TOL-2 Trial of MIC-Lx, Advancing a New Immune Tolerance Approach in Kidney Transplantation
TolerogenixX has completed the transplantation phase of its Phase IIb clinical trial for MIC-Lx, a therapy designed to induce immune tolerance in kidney transplant recipients. The company aims to reduce the need for lifelong immunosuppressive drugs and plans to release topline data in 2027.
Why it matters
If successful, this therapy could significantly improve the quality of life for transplant patients by reducing the toxicity and infection risks associated with current standard-of-care immunosuppressants.
Kidney transplantation saves lives, but patients typically need lifelong systemic immunosuppression. These drugs increase infection risk, add toxicity and create a major long-term treatment burden. MIC-Lx is designed to address this core limitation by teaching the immune system to accept the donor organ while preserving its protective immune function.
The article is a factual summary of a clinical trial milestone based on a corporate press release.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in